Koaⁿ tōng-me̍h sng-sek su̍t

Lohankhapedia (自由的百科全書) 欲共你講..。
跳至導覽 跳至搜尋
官動脈酸式術
Other names HAE， trans-arterial embolization， TAE
Specialty interventional radiology/oncology
[[[d:Pang-bô͘:Wikidata|edit on Wikidata]]]

肝 (Kuann)動脈 (tōng-me̍h)栓塞 (sng-sik)術 (su̍t) (英語 (ing-gú): Hepatic artery embolization; 漢語 (hàn-gú): 肝動脈栓塞術; Kuann tōng-me̍h sng-sat su̍t)， mā kiò-tsò king-iû kuann tōng-me̍h sng-sik su̍t (trans-arterial embolization (TAE))，是 (sī)佇療 (tī-liâu)原發性 (guân-huat-sìng)肝臟 (kuann-tsōng)種流 (tsíng-liû)或者 (hi̍k-tsiá)官狀 (kuann-tsōng)腫瘤 (tsíng-liû) Pang-bô͘:Ill的 (ê)規種 (kui-tsióng)佇療方法 (hong-huat)之一 (tsi-it)。Pang-bô͘:Ill治療 (tī-liâu)會當 (ē-tàng)速小 (sok-sió)腫瘤的大細 (tuā-sè); 並且 (pīng-tshiánn)減少 (kiám-tsió)種流對 (tuì)極數 (ki̍k-sòo)產生 (sán-sing)的影響 (íng-hióng)，有校 (ū-hāu)減輕 (kiám-khin)政臟 (tsìng-tsōng); 這个 (tsit-ê)療法 (liâu-huat)上頭仔 (siōng-thâu-á)開發 (khai-huat)佇 (tī)20世紀 (sè-kí)70年代 (nî-tāi)初期 (tshoo-kî).[1] 幾也 (Kuí-ā)種 (tsióng)類型 (luī-hîng)的官 (kuann)動脈佇療徛 (khiā)佇以下 (í-hā)的觀察 (kuan-tshat): 種流世包 (sè-pau)差不多 (tsha-put-to)對 (uì)官動脈得取 (tit-tshú)所有 (sóo-ū)的營養 (îng-ióng); 而且 (lî-tshiánn)正常 (tsìng-siông)的官細胞 (sè-pau)對官動脈得取代約 (tāi-iok)70-80% 个 (ê)榮養 (îng-ióng)和 (hām)50% 个送數 (sàng-sòo)供應 (kiong-ìng)靜脈 (tsīng-me̍h)。因此 (In-tshú)會使 (ē-sái)咧 (teh)官動脈有效 (ū-hāu)阻斷 (tsóo-tn̄g)的情況 (tsîng-hóng)生存 (sing-tsûn).[2] 咧實踐 (si̍t-tsiān)當中 (tang-tiong)，官動脈酸色 (sng-sik)祖斷 (tsóo-tn̄g)流對 (lâu-uì)腫瘤的血瘤 (hiat-liû),[3] 致使 (tì-sú)超過 (tshiau-kuè)80% 个人 (lâng)怹的 (in-ê)整瀏 (tsíng-liû)顯著 (hián-tù)縮小 (sok-sió).[3] 修速 (Siu-sok)率 (lu̍t)逐 (ta̍k)的人攏 (lóng)無 (bô)相仝 (sio-kâng).[4][5]

注 (Tsù)káis[修改]

  1. ↑ Del Prete, Michela; Fiore, Francesco; Modica, Roberta; Marotta, Vincenzo; Marciello, Francesca; Ramundo, Valeria; Di Sarno, Antonella; Carratù, Annachiara; Di Roseto, Chiara; Tafuto, Salvatore; Tatangelo, Fabiana; Baldelli, Robero; Colao, Annamaria; Faggiano, Antongiulio (2014). "Hepatic arterial embolization in patients with neuroendocrine tumors". Journal of Experimental & Clinical Cancer Research. 33 (1): 43. doi:10.1186/1756-9966-33-43. PMC 4038067 Freely accessible. PMID 24887262. 
  2. ↑ Pommier R。 2003。 The role of surgery and chemoembolization in the management of carcinoid。 California Carcinoid Fighters Conference。 October 25， http://www.carcinoid.org/content/role-surgery-and-chemoembolization-management-carcinoid
  3. ↑ 3.0 3.1 Kvols LK。 2002。 Carcinoid Tumors and the Carcinoid Syndrome: What's New in the Therapeutic Pipeline。 (The Carcinoid Cancer Foundation: Carcinoid Symposium 2002)http://www.carcinoid.org/content/carcinoid-tumors-and-carcinoid-syndrome-whats-new-therapeutic-pipeline
  4. ↑ Gu, 冰; Wu, Jennifer; Newman, Elliot; Muggia, Franco (2012). "Treatment of Liver Metastases in Patients with Neuroendocrine Tumors of Gastroesophageal and Pancreatic Origin". International Journal of Hepatology. 2012: 1–8. doi:10.1155/2012/131659. PMC 3299245 Freely accessible. PMID 22518318. 
  5. ↑ Lewis, M。 A; Jaramillo, S; Roberts, L; Fleming, C。 J; Rubin, J; Grothey, A (2012). "Hepatic Artery Embolization for Neuroendocrine Tumors: Postprocedural Management and Complications". The Oncologist. 17 (5): 725–31. doi:10.1634/theoncologist.2011-0372. PMC 3360912 Freely accessible. PMID 22511263. 

參閱 (Tsham-ua̍t)[修改]

  • Neuroendocrine tumor
  • Carcinoid syndrome
  • 酸色術 (Embolization)
  • 遠單 (Uán-tuann)轉移 (tsuán-î) (Metastasis)

外部 (Guā-pōo)連結 (liân-kiat)[修改]

來源: "https://taigi.lohankhapedia.org/w/index.php?title=Koaⁿ_tōng-me̍h_sng-sek_su̍t&oldid=3071740"